Evidence map›Paper›PMID 27061069›Full record

ArticleJournal of Parkinson's disease2016

APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Kimberly C Paul, Rebecca Rausch, Michelle M Creek, Janet S Sinsheimer, Jeff M Bronstein, Yvette Bordelon, Beate Ritz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The role ofFrontiers in neuroscience · 2025
    Review
  10. Article
  11. GWAS Identifies DPP6 as Risk Gene of Cognitive Decline in Parkinson's Disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Article
  12. Apolipoprotein E Gene in α-Synucleinopathies: A Narrative Review.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kimberly C PaulDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Rebecca RauschDepartment of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA.
Michelle M CreekDepartment of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Janet S SinsheimerDepartment of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Jeff M BronsteinDepartment of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA.
Yvette BordelonDepartment of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA.
Beate RitzDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
University of California, Los Angeles · USUCLA Health · US

Funding

UCLA CENTER FOR THE STUDY OF PARKINSON'S DISEASEP50NS038367 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHESSELET, MARIE-FRANCOISE S · 1999 to 2011
$15.3M
STATISTICAL METHODS FOR GENE MAPPINGR01GM053275 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LANGE, KENNETH L · 1995 to 2019
$9.3M
Center for Gene-Environment Studies in Parkinson DiseaseU54ES012078 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHESSELET, MARIE-FRANCOISE S · 2002 to 2006
$7.1M
PARKINSON'S DISEASES SUSCEPTIBILITY GENES AND PESTICIDESR01ES010544 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RITZ, BEATE R. · 2000 to 2015
$5.7M
NIEHS NIH HHS R01 ES010544NIEHS NIH HHS U54 ES012078NIGMS NIH HHS R01 GM053275NINDS NIH HHS P50 NS038367
6 · The paper itself

Abstract

backgroundCognitive decline is well recognized in Parkinson's disease (PD) and a major concern for patients and caregivers. Apolipoprotein E (APOE), catechol-O-methyl transferase (COMT), and microtubule-associated protein tau (MAPT) are of interest related to their contributions to cognitive decline or dementia in PD.

objectiveHere, we investigate whether APOE, COMT, or MAPT influence the rate of cognitive decline in PD patients.

methodsWe relied on 634 PD patients and 879 controls to examine gene-PD susceptibility associations, and nested longitudinal cohort of 246 patients from the case-control study, which followed patients on average 5 years and 7.5 years into disease. We repeatedly assessed cognitive symptom progression with the MMSE and conducted a full neuropsychological battery on a subset of 183 cognitively normal patients. We used repeated-measures regression analyses to assess longitudinal associations between genotypes and cognitive progression scores.

resultsThe MAPT H1 haplotype was associated with PD susceptibility. APOE 4 carriers (ɛ4+) (p = 0.03) and possibly COMT Met/Met (p = 0.06) carriers exhibited faster annual decline on the MMSE. Additionally, APOEɛ4+ carriers showed faster decline in many of the neuropsychological test scores. No such differences in neuropsychological outcomes were seen for the COMT genotypes.

conclusionThis work supports a growing set of research identifying overlapping etiology and pathology between synucleinopathies, such as PD, Alzheimer's disease, and tauopathies, especially in the context of cognitive dysfunction in PD. We provide support for the argument that APOE ɛ4+ and COMT Met/Met genotypes can be used as predictors of faster cognitive decline in PD.

Indexed as

Genetic Predisposition to DiseaseAgedApolipoproteins ECatechol O-MethyltransferaseCognitionDisease ProgressionFemaleGenotypeHumansMaleMiddle AgedParkinson DiseasePolymorphism, Single Nucleotidetau ProteinsApoE protein, humanApolipoproteins ECatechol O-MethyltransferaseCOMT protein, humanMAPT protein, humantau ProteinsAPOEcognitioncognitive declineCOMTMAPTParkinson’s disease

Identifiers

PMID27061069
PMCPMC5927361
OpenAlexW2342056047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.